Chronic Lymphocytic Leukemia News and Research

RSS

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.

Combination of venetoclax and standard therapies shows promise in high-risk myeloid blood cancers

The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.

7 Dec 2020

Grants give military veterans better access to cancer clinical trials

SWOG Cancer Research Network and its charity, The Hope Foundation for Cancer Research, announce the award of two grants designed to give military veterans better access to cancer clinical trials.

11 Nov 2020

Commonly prescribed anti-depressant may halt the growth of childhood sarcoma

A new study has found that a commonly prescribed anti-depressant may halt growth of a type of cancer known as childhood sarcoma, at least in mice and laboratory cell experiments.

6 Nov 2020

Case study reports prolonged infectious SARS-CoV-2 shedding from an asymptomatic leukemia patient

The majority of people infected with SARS-CoV-2 appear to actively shed infectious virus for about 8 days, but there is a wide range of variability from person to person.

4 Nov 2020

Researchers are developing a new class of compounds against various cancers

Researchers at The Wistar Institute and collaborators from the University of Notre Dame are developing anticancer compounds targeting a pathway of the endoplasmic reticulum (ER) stress response implicated in the development of multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and lymphoma.

14 Oct 2020

Calibr's novel 'switchable' CAR-T cell therapy granted FDA's Fast Track designation

The U.S. Food and Drug Administration has granted Fast Track designation to a novel "switchable" CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process.

1 Oct 2020

Researchers unravel new mechanism of cell survival in chronic lymphocytic leukemia

Researchers at The Wistar Institute unraveled a mechanism employed by chronic lymphocytic leukemia (CLL) cells for their survival.

30 Sep 2020

COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies

A recent case study published in the Journal of Applied Laboratory Medicine in August 2020 illustrates this with its finding of persistent seronegativity in a patient confirmed to be SARS-CoV-2 positive.

10 Aug 2020

Clinical study evaluates potential of oral cancer drug to reduce respiratory symptoms of COVID-19

Researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and The Ohio State University Wexner Medical Center are conducting a new clinical trial to determine if an oral cancer drug called ibrutinib can also help patients with cancer or other immunocompromised conditions recover from COVID-19.

29 Jul 2020

Dual inhibitor therapy may be safer for CLL patients, Moffitt study shows

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. One in four new leukemia cases are CLL.

14 Jul 2020

New NCCN guidelines explain how to recognize and manage immunotherapy-related side effects

The National Comprehensive Cancer Network today announced the completion of the new NCCN Guidelines for Patients®: Immunotherapy Side Effects series, with the publication of a book focused on chimeric antigen receptor (CAR) T-cell therapy. This closely follows the publication of a separate book on immune checkpoint inhibitors, both created with support from the NCCN Foundation®.

1 Jul 2020

New drug can prevent life-threatening anaphylaxis, shows study

For someone with a food or drug allergy, the risk of life-threatening anaphylactic shock lurks around every corner. A new Northwestern Medicine study shows there might be a pill that can be taken proactively to prevent mild to life-threatening anaphylaxis, no matter the cause.

3 Jun 2020

Dana-Farber launches clinical test of blood cancer drug in COVID-19 patients

Scientists at Dana-Farber Cancer Institute have launched a clinical test of a blood cancer drug in patients infected with the COVID-19 virus. T

20 May 2020

Drug combo for untreated CLL approved by FDA based on E1912 trial

Patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma now have a new treatment option--a combination of the targeted agent ibrutinib with the immunologic agent rituximab.

29 Apr 2020

Greater occurrence of infections correlates with future cancer diagnosis

Patients experienced a greater occurrence of infections in the years preceding a cancer diagnosis.

17 Apr 2020

New prognostic tool could help improve clinical decision making for leukemia patients

A new prognostic tool predicts how long someone diagnosed with chronic lymphocytic leukemia (CLL) will be able to wait before starting cancer treatment.

8 Apr 2020

New prognostic tool helps leukemia patients plan for cancer treatment

A prognostic tool predicts how long someone diagnosed with chronic lymphocytic leukemia (CLL) can wait before cancer treatment.

8 Apr 2020

Single gene cluster loss promotes initiation and progression of multiple myeloma in mice

The loss of one copy of the miR15a/miR16-1 gene cluster promoted initiation and progression of multiple myeloma in mice.

20 Feb 2020

Universal 'One-Size-Fits-All' Cancer Treatment

Andrew Sewell speaks to News-Medical about his breakthrough research, in which he has discovered a new T-Cell that could treat most cancers.

14 Feb 2020

CD19 CAR NK cell therapy clinical trial shows encouraging results for hematologic cancers

According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia, with no major toxicities observed.

6 Feb 2020